Natto: NattoPharma’s MenaQ7™ PURE has obtained Novel Food approval from EFSA
Høvik, Norway (April 15, 2015). NattoPharma ASA has today, Wednesday 15th April 2015, received written information from the Policy officer in the European Commission, DG Health and Food Safety, communicating that MenaQ7 PURE has received Novel Food approval by EFSA. As per the date of the NattoPharma Prospectus, April 10th 2015, such approval was not received.
“This Novel Food approval is very good news for NattoPharma and of material importance for our sales and marketing of MenaQ7 PURE in Europe. The approval also represents a “quality stamp” for our world-wide distributors. By offering MenaQ7 PURE to customers in Europe NattoPharma will further strengthen our competitive edge”, says Hogne Vik, CEO in NattoPharma.
The MenaQ7 PURE product is a high quality product with efficient production costs. In combination with high quality this product is a good option for customers requiring low cost products, either by introducing MenaQ7 into existing products or by developing new product lines. NattoPharma considers that the largest potential for growth and increased revenues are within the synthetic products market within these segments, requiring huge volumes of MenaQ7 material
According to Hogne Vik this has been a long process. “The application was filed April 2014, and it has taken close to one year to come through with an approval for our product. However, the approval came in due time. A full European launch of MenaQ7 PURE will take place in the upcoming Vitafoods Fair in Geneva, Switzerland in beginning of May 2015, where NattoPharma will be present with our own booth”.
# # #
About MenaQ7®
MenaQ7® is the best documented, commercially available natural vitamin K2 with guaranteed actives and stability, clinical substantiation and international patents granted and pending. For more information on the health benefits of MenaQ7, visit menaq7.com.
About NattoPharma
NattoPharma USA, Inc. is the wholly owned U.S. subsidiary of NattoPharma ASA, Norway, which is the world’s leader in vitamin K2 research and development. NattoPharma is the exclusive international supplier of MenaQ7®, the natural vitamin K2 as MK-7, and the company has been in a multi-year research and development program to substantiate and discover the health benefits of natural vitamin K2 for applications in the marketplace for functional food and dietary supplements. For more information, visit nattopharma.com.
For more information, please contact:
Hogne Vik, CEO NattoPharma
Cell phone: +47 97 53 53 26
E-mail: hogne.vik@nattopharma.com
Tags: